Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Institutes of Health Clinical Center (CC) Identifier:
First received: August 13, 2008
Last updated: March 14, 2012
Last verified: March 2012